Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 16;5(6):813-820.
doi: 10.1016/j.ekir.2020.03.012. eCollection 2020 Jun.

Spondyloarthritis-Associated IgA Nephropathy

Affiliations

Spondyloarthritis-Associated IgA Nephropathy

Nicolas Champtiaux et al. Kidney Int Rep. .

Abstract

Introduction: IgA nephropathy (IgAN) can be associated with spondyloarthritis (SpA). The course of SpA-associated IgAN remains largely unknown due to the absence of large cohorts.

Methods: This retrospective study included patients with biopsy-proven IgAN and definite SpA. Kidney biopsies were centrally examined and scored according to the IgAN Oxford Classification. Thirty-two patients fulfilled the inclusion criteria, with a male:female ratio of 9:1 and median age of 27 and 37 years at SpA and IgAN diagnosis, respectively. HLA-B27 was positive in 90% of cases, and most patients (60%) presented with ankylosing spondylitis. The mean baseline estimated glomerular filtration rate (eGFR) was 84 ± 26 ml/min per 1.73 m2, and the urine protein-to-creatinine ratio was 0.19 g/mmol.

Results: Renal biopsy revealed frequent presence of crescents (33%) and interstitial inflammation (18%). Despite almost constant use of renin-angiotensin system inhibitors, combined with steroids in 13 of 32 patients, renal outcome was particularly poor. After a median follow-up of 5.9 years, 4 patients (12.5%) reached end-stage renal disease and 41% of patients experienced a >50% decrease of eGFR. The mean annual eGFR decline rate was -4.3 ± 6.7 ml/min per 1.73 m2. The risk of reaching class IV or V chronic kidney disease (CKD) stage during follow-up was associated with the presence of hypertension, level of proteinuria, and baseline S- and T-scores of the Oxford.

Conclusion: SpA-associated IgAN is associated with a poor renal outcome, despite frequent use of steroids. Tumor necrosis factor (TNF)-α blockade did not appear to influence the rate of eGFR decline in this setting.

Keywords: IgA nephropathy; NSAIDs; TNF-α blockers; ankylosing spondylitis; renal failure; spondyloarthritis.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Survival without reaching the combined renal endpoint (chronic kidney disease stage 4 or 5 and/or doubling of serum creatinine). Circles represent censored data. The shaded zone represents the 95% confidence interval.
Figure 2
Figure 2
Effect of anti–tumor necrosis factor α (TNFα) treatment on estimated glomerular filtration rate (eGFR) decline rate (a) and proteinuria (b). When possible (n = 8 patients), the eGFR decline rate and urine protein-to-creatinine ratio (PCR) were calculated before and after anti-TNFα treatment. Dashed lines represent individual patients. Solid gray line represents the average value. Vertical bars represent the SE.

Comment in

References

    1. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;64:709–727. - PubMed
    1. Strobel E.S., Fritschka E. Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol. 1998;17:524–530. - PubMed
    1. Montenegro V., Monteiro R.C. Elevation of serum IgA in spondyloarthropathies and IgA nephropathy and its pathogenic role. Curr Opin Rheumatol. 1999;11:265–272. - PubMed
    1. Montenegro V., Chiamolera M., Launay P. Impaired expression of IgA Fc receptors (CD89) by blood phagocytic cells in ankylosing spondylitis. J Rheumatol. 2000;27:411–417. - PubMed
    1. Peeters A.J., van den Wall Bake A.W., van Dalsen A.D. Relation of microscopic haematuria in ankylosing spondylitis to circulating IgA containing immune complexes. Ann Rheum Dis. 1988;47:645–647. - PMC - PubMed